Why the study?
LECT2 is associated with metabolic disorders that pose a risk for arteriosclerosis, but its relationship with CAD severity and prognosis required assessment.
Are plasma LECT-2 levels associated with the presence, severity, and prognosis of coronary artery disease?
Cross-Sectional (n=666)
No
Are plasma LECT-2 levels associated with the presence, severity, and prognosis of coronary artery disease?
Plasma LECT-2 levels are elevated in patients with coronary artery disease, correlate with angiographic disease severity, and predict 12-month MACE in patients with acute myocardial infarction.
LECT2 may aid CAD stratification; leaves open its diagnostic utility pending prospective validation.
Many studies have shown that leukocyte cell-derived chemotaxin 2 (LECT2) is associated with metabolic disorders, which is a risk factor of arteriosclerosis. We assessed the level of LECT-2 in patients with coronary artery disease (CAD) and its severity and prognosis. We selected 666 participants who underwent coronary angiography in our hospital and included patients with non-CAD, patients with stable angina pectoris (SAP), patients with unstable angina (UA), patients with non-ST-segment elevation myocardial infarction (NSTEMI) and patients with ST-segment elevation myocardial infarction (STEMI). The serum level of LECT-2 was higher in patients with CAD than in patients with non-CAD and was an independent predictor for CAD. Subgroup analysis showed that compared with the SAP group, the UA, NSTEMI, and STEMI groups had higher serum levels of LECT-2. In addition, the level of LECT-2 was related to the SYNTAX score and SYNTAX II score. Finally, patients with acute myocardial infarction (AMI) with elevated levels of LECT-2 had a higher risk of major adverse cardiovascular events (MACEs) within 12 months than those with lower levels of LECT-2. Plasma LECT-2 levels may be useful for the diagnosis of CAD and as predictors of MACE in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2021) conducted a cross-sectional in Coronary Artery Disease (CAD) (n=666). Elevated plasma Leukocyte Cell-Derived Chemotaxin 2 (LECT2) vs. Lower levels of LECT-2 / non-CAD was evaluated on Presence of CAD and major adverse cardiovascular events (MACEs).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: